Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(62.5%)
Phase 3
2(25.0%)
Phase 1
1(12.5%)
8Total
Phase 2(5)
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT01452815Phase 2Completed

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Role: lead

NCT01664637Phase 2Terminated

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

Role: lead

NCT00889486Phase 2Completed

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Role: lead

NCT00617552Phase 2Completed

Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery

Role: lead

NCT00612014Phase 2Completed

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis

Role: lead

NCT01296620Phase 3Completed

Ulimorelin Study of Efficacy and Safety (ULISES 008)

Role: lead

NCT01285570Phase 3Completed

Ulimorelin Study of Efficacy and Safety (ULISES 007)

Role: lead

NCT01316484Completed

Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms

Role: lead

NCT00639808Phase 1Completed

Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis

Role: lead

All 9 trials loaded